EMD Millipore's new Drypour packaging system helps minimize caking of pharmaceutical raw materials.
EMD Millipore, the life-science division of Merck KGaA, has introduced the Drypour packaging system, which minimizes caking during transport and storage of hygroscopic salts used in pharmaceutical manufacturing. The system, which consists of a polyethylene drum with a tamper-evident seal, apolyethylene liner with integrated desiccant bags, and a breathable interior Tyvek liner, helps improve operational efficiency by reducing the time and effort needed to break up heavily caked raw materials, according to the company.
The drum and polyethylene liner prevent outside moisture from entering the product. Any water vapor in the product itself can permeate the interior, tear-resistant Tyvek liner, migrate into the outer polyethylene liner and be absorbed by the integrated desiccant. Unlike other packaging systems, the desiccant bags in the Drypour system are fixed to the perforated polyethylene liner, thus preventing contact with the product, so product quality is not compromised, according to the company. For maximum effect, the desiccant bags are mounted in varying places on the liner.
A range of the company's line of Emprove pharmaceutical raw materials is available in the Drypour packaging system. The Drypour system is available in 100-kilogram package sizes and can be moved with common handling devices. The system meets both European Pharmacopoeia and USP requirements.
Source: EMD Millipore
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications
December 10th 2024This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.